IL149151A0 - Treatment of emphysema using rar selective retinoid agonists - Google Patents

Treatment of emphysema using rar selective retinoid agonists

Info

Publication number
IL149151A0
IL149151A0 IL14915100A IL14915100A IL149151A0 IL 149151 A0 IL149151 A0 IL 149151A0 IL 14915100 A IL14915100 A IL 14915100A IL 14915100 A IL14915100 A IL 14915100A IL 149151 A0 IL149151 A0 IL 149151A0
Authority
IL
Israel
Prior art keywords
emphysema
treatment
retinoid agonists
rar selective
selective retinoid
Prior art date
Application number
IL14915100A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL149151A0 publication Critical patent/IL149151A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14915100A 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists IL149151A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (1)

Publication Number Publication Date
IL149151A0 true IL149151A0 (en) 2002-11-10

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14915100A IL149151A0 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Country Status (34)

Country Link
US (1) US6300350B1 (zh)
EP (1) EP1225878B1 (zh)
JP (2) JP4074458B2 (zh)
KR (1) KR100485581B1 (zh)
CN (1) CN1201730C (zh)
AR (1) AR029648A1 (zh)
AT (1) ATE344661T1 (zh)
AU (1) AU777325B2 (zh)
BR (1) BR0015225A (zh)
CA (1) CA2387844C (zh)
CY (1) CY1105941T1 (zh)
CZ (1) CZ20021657A3 (zh)
DE (1) DE60031790T2 (zh)
DK (1) DK1225878T3 (zh)
ES (1) ES2274810T3 (zh)
HK (1) HK1051002A1 (zh)
HR (1) HRP20020329A2 (zh)
HU (1) HUP0203295A3 (zh)
IL (1) IL149151A0 (zh)
JO (1) JO2178B1 (zh)
MA (1) MA26835A1 (zh)
MX (1) MXPA02003843A (zh)
MY (1) MY129001A (zh)
NO (1) NO328738B1 (zh)
NZ (1) NZ518118A (zh)
PE (1) PE20010678A1 (zh)
PL (1) PL357499A1 (zh)
PT (1) PT1225878E (zh)
RS (1) RS50165B (zh)
RU (1) RU2257383C2 (zh)
TR (1) TR200201071T2 (zh)
TW (1) TWI288639B (zh)
WO (1) WO2001030326A1 (zh)
ZA (1) ZA200202576B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
KR100891224B1 (ko) 2001-09-18 2009-04-01 에프. 호프만-라 로슈 아게 치환된 우레아 레티노이드 작용제 ⅱ
AU2002329276B2 (en) 2001-09-18 2008-04-24 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists I
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
US20100222304A1 (en) * 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
BR112013033309B1 (pt) 2011-06-24 2022-07-05 Gri Bio, Inc Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9963439B2 (en) 2013-08-20 2018-05-08 University Of Washington Through Its Center For Commercialization Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
EP3039126B1 (en) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) * 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
DE69835441T2 (de) * 1997-11-12 2007-08-02 F. Hoffmann-La Roche Ag Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
WO2000061232A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
ATE279386T1 (de) * 1999-08-02 2004-10-15 Hoffmann La Roche Retinoide zur behandlung von emphysem
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
KR100485581B1 (ko) 2005-04-27
CA2387844C (en) 2009-04-14
NO20021823L (no) 2002-04-18
ZA200202576B (en) 2003-09-23
RU2257383C2 (ru) 2005-07-27
DE60031790D1 (de) 2006-12-21
PL357499A1 (en) 2004-07-26
CA2387844A1 (en) 2001-05-03
AU1137401A (en) 2001-05-08
HK1051002A1 (en) 2003-07-18
BR0015225A (pt) 2002-07-16
HRP20020329A2 (en) 2004-04-30
JP4074458B2 (ja) 2008-04-09
NZ518118A (en) 2004-02-27
WO2001030326A1 (en) 2001-05-03
YU29002A (sh) 2005-06-10
CY1105941T1 (el) 2011-04-06
DE60031790T2 (de) 2007-09-20
RS50165B (sr) 2009-05-06
JO2178B1 (en) 2003-04-23
TR200201071T2 (tr) 2002-08-21
CN1382042A (zh) 2002-11-27
KR20020043640A (ko) 2002-06-10
HUP0203295A3 (en) 2003-04-28
AU777325B2 (en) 2004-10-14
ATE344661T1 (de) 2006-11-15
DK1225878T3 (da) 2007-03-05
AR029648A1 (es) 2003-07-10
CZ20021657A3 (cs) 2002-10-16
PT1225878E (pt) 2007-01-31
US6300350B1 (en) 2001-10-09
MA26835A1 (fr) 2004-12-20
JP2003512418A (ja) 2003-04-02
MY129001A (en) 2007-03-30
JP2007302689A (ja) 2007-11-22
NO20021823D0 (no) 2002-04-18
JP4850791B2 (ja) 2012-01-11
ES2274810T3 (es) 2007-06-01
PE20010678A1 (es) 2001-07-04
EP1225878A1 (en) 2002-07-31
CN1201730C (zh) 2005-05-18
MXPA02003843A (es) 2002-09-30
HUP0203295A2 (hu) 2003-01-28
TWI288639B (en) 2007-10-21
NO328738B1 (no) 2010-05-03
EP1225878B1 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
IL149151A0 (en) Treatment of emphysema using rar selective retinoid agonists
AU3660699A (en) Uterine treatment apparatus
IL149874A0 (en) Selective photothermolysis
HU0001471D0 (en) New method of treatment
HUP0103545A3 (en) Wound treatment apparatus
AU2002210293A1 (en) Continuous water cycle water treatment apparatus
GB2358769B (en) Communications apparatus
AU2001295032A1 (en) Iontophoretic apparatus
IL145875A0 (en) Novel method of treatment
GB9919668D0 (en) Elongate personal communications apparatus
IL161005A0 (en) Neuroprotective treatment methods using selective inos inhibitors
AUPQ989400A0 (en) Water treatment apparatus
GB9930772D0 (en) Communications apparatus
SG89379A1 (en) Treatment apparatus
GB0026838D0 (en) Treatment method
GB9930688D0 (en) Novel method of treatment
AU2504101A (en) Device for carrying out the oscillation-induced selective treatment of malignantdiseases
SI1225878T1 (sl) Rar-gama selektivni retinoidni agonisti za zdravljenje emfizema
GB0017153D0 (en) Extinguishing apparatus
EP1303281A4 (en) METHODS OF TREATMENT
AU2002223293A1 (en) Water treatment apparatus
GB9930696D0 (en) Novel method of treatment
GB0005262D0 (en) Alarm apparatus
TW385708U (en) Fire-fighting apparatus and its water-supplying apparatus
GB9917181D0 (en) Methods of treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees